Lilly Targets Actavis In Latest Cymbalta Patent Suit

Law360, New York (November 19, 2008, 12:00 AM EST) -- Eli Lilly and Co. added a fifth generic-drug maker to its bid to block competing versions of its antidepressant Cymbalta Tuesday, suing Actavis Elizabeth LLC over a patent for the blockbuster drug less than a week after filing four similar suits.

The complaint, filed in the U.S. District Court for the Southern District of Indiana, claims that Actavis filed an abbreviated new drug application with the U.S. Food and Drug Administration seeking to sell its generic delayed release version of duloxetine hydrochloride in three dosages before...
To view the full article, register now.